Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Jun 8, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2017-06-06

Reporting Person: SKIBSTED RUSSELL (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-06	Option to Purchase Common Shares	$3.16	A	250000	Acquired	2027-06-05	Common Shares (250000)	Direct

Footnotes

F1: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2018, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2018, based upon continued service.